Real-world prevalence of microsatellite instability testing and related status in women with advanced endometrial cancer in Europe.

Sneha S KelkarVimalanand Shrikant PrabhuJingchuan ZhangYoscar M OgandoKyle RoneyRishi P VermaNicola MilesChristian Marth

Published in: Archives of gynecology and obstetrics (2024)

Prior to the approvals of biomarker-directed therapies for recurrent/advanced endometrial cancer patients in Europe, there were low MSI/MMR testing rates for these patients of just over one-third. Given the availability of biomarker-directed therapies, increased MSI/MMR testing may help inform treatment decisions for recurrent/advanced endometrial cancer patients in Europe.

Keyphrases

endometrial cancer
end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
risk factors
prognostic factors
patient reported outcomes
patient reported